Evidence for the Presynaptic Localization of Opiate Binding Sites on Striatal Efferent Fibers

B. ABOU-KHALIL, A. B. YOUNG and J. B. PENNEY

University of Michigan, Department of Neurology, Ann Arbor, MI 48109 (U.S.A.)

(Accepted March 27th, 1984)

Key words: opiates --- receptors --- striatum --- globus pallidus --- presynaptic receptors --- D-Ala-d-Leu-enkephalin --- naloxone

Using quantitative receptor autoradiography, [3H]D-Ala-d-Leu-enkephalin (DADL) and [3H]naloxone binding were studied in rat striatum and striatal projection areas (globus pallidus (GP) and substantia nigra pars reticulata (SNr)) after unilateral striatal kainic acid lesions. [3H]DADL and [3H]naloxone binding were each examined by two methods. Initially, [3H]DADL binding was performed in 50 mM Tris-HCl (pH 7.4), 30 mM NaCl, 3 mM manganese acetate and 2 μM GTP; [3H]naloxone binding was carried out in 50 mM Tris-HCl (pH 7.4) and 100 mM NaCl. Subsequent studies were carried out in 150 mM Tris-HCl (pH 7.4) and either [3H]DADL plus 500 nM morphiceptin (to block [3H]DADL binding to mu receptors) or [3H]naloxone plus 10 nM delta receptor peptide (to block [3H]naloxone binding to delta receptors). At one and eight weeks in the lesioned striatum, [3H]DADL binding was reduced by 70% and 82%, respectively, when compared to the control side. [3H]Naloxone binding was reduced by 35% and 20%, respectively, when compared to the control side. [3H]Naloxone binding was reduced by 70% and 82%, respectively, when compared to the control side. At one week and 27% and 26% at eight weeks. [3H]Naloxone binding was reduced 19% in GP at eight weeks. A parsimonious explanation of these results is that opiate binding sites are located on presynaptic terminals of striatal efferent fibers to globus pallidus and substantia nigra pars reticulata as well as on local striatal axon collaterals. Since opiate peptides have recently been found to coexist with GABA in some striatal neurons, opiate peptides may play a role in striatal function by controlling GABA release from striatal efferent fibers. It is possible that pallidal and nigral opiate binding could be utilized as a marker for striatal terminals.

INTRODUCTION

Neurons and presynaptic terminals in the striatum contain high concentrations of enkephalin-like immunoreactivity. There are also high levels of enkephalin in the lateral globus pallidus (GP) and some is present in the substantia nigra pars reticulata (SNr). Immunohistochemical studies suggest that the enkephalin in GP and SNr is located primarily in presynaptic terminals. The peptide is released from these terminals after electrical stimulation of caudate nucleus. After striatal lesions or deafferentation, enkephalin levels in GP and SNr fall markedly. Taken together, this evidence suggests that there is a major enkephalinergic pathway from the striatum to the GP and a lesser pathway to SNr.

Despite this evidence for an enkephalinergic striatopallidal and striatonigral pathway in rat, only low levels of both mu and delta opiate receptors have been found in the GP and SNr. In contrast, high levels of mu and delta opiate receptors have been observed in striatum. Some striatal opiate receptors appear to be localized on the axon terminals of dopaminergic and serotonergic striatal afferent fibers and may function to control dopamine and serotonin release. However, the role of opiates and opiate receptors in striatal function and output is largely unknown. We have measured opiate receptors in the striatum and the primary striatal projection areas after destruction of striatal neurons with kainic acid.

METHODS

Male Sprague–Dawley rats weighing 150–200 g...
were anesthetized with 7 mg/kg xylazine and 100 mg/kg ketamine (i.p.). Kainic acid lesions were made according to our previously described method. Kainic acid (Sigma), 0.1 M, adjusted to pH 7.0 with HCl, was applied iontophoretically into the right striatum of these rats by passing negative current (5 μA) in 500 ms on/500 ms off pulses for 5 min through a glass micropipette tip with an inner diameter of 50 μm. Angled injections from 30° forward of vertical passing through prefrontal cortex were made using a David Kopf small animal stereotaxic device. The pipette tip was placed 2.0 mm anterior, 3.0 mm lateral and 4.2 mm ventral to Bregma with the incisor bar 5 mm above the ear bars (AP + 8.0 mm, ML + 3.0 mm, DV + 1.0 mm) according to the atlas of König and Klippel.

In initial studies, rats were decapitated 7-10 days after the striatal lesion, the brains were quickly removed, mounted on microtome chucks with Lipshaw frozen embedding medium, and frozen at -20 °C. Twenty-μm thick coronal sections of the brains were cut in a cryostat (Lipshaw) and thaw-mounted onto detergent cleaned, gelatin-coated microscope slides. Slides were kept frozen at -20 °C overnight. The next day, serial sections through the lesion, globus pallidus and substantia nigra were washed twice for 5 min each in cold buffer and then blown dry in a stream of cool air. Sections were incubated with [3H]naloxone (1-5 nM) in 50 mM Tris HCl (pH 7.4) and 100 mM NaCl at 4 °C for 1 h to preferentially label mu opiate receptors, or with [3H]D-Ala-D-Leu-enkephalin (DADL) (1-8 nM) in 50 mM Tris HCl, 30 mM NaCl, 3 mM manganese acetate and 2 μM GTP at 20 °C for 30 min according to the method of Lewis et al. Selected sections were postfixed over paraformaldehyde vapors and stained with cresyl violet to assure that the lesions did not extend into the globus pallidus. Sections were also analyzed by computer-assisted methods to measure the approximate size of the striatal lesions.

The incubation conditions described above label mu and delta receptors relatively selectively and the various ion and nucleotide concentrations were used to maximize the number of binding sites labeled. It was also considered important to study opiate receptors using drugs which would preferentially block delta receptor binding during [3H]naloxone binding and and 5:1 for [3H]DADL; in substantia nigra pars reticulata, the ratio was 4.5:1 for [3H]naloxone binding and 3.5:1 for [3H]DADL.

Selected sections were postfixed over paraformaldehyde vapors and stained with cresyl violet to assure that the lesions did not extend into the globus pallidus. Sections were also analyzed by computer-assisted methods to measure the approximate size of the striatal lesions.

The incubation conditions described above label mu and delta receptors relatively selectively and the various ion and nucleotide concentrations were used to maximize the number of binding sites labeled. It was also considered important to study opiate receptors using drugs which would preferentially block delta receptor binding during [3H]naloxone binding and [3H]DADL binding studies and mu receptor binding during [3H]DADL binding studies. These assays used different buffer and incubation conditions from the first assays. It was ascertained that 10 nM delta receptor peptide would block 80-90% of [3H]DADL binding but only a 20-30% of [3H]naloxone binding. Likewise, it was determined that a 500 nM concentration of morphine would block 80-90% of [3H]naloxone binding but only 10-20% of [3H]DADL binding.
Additional animals were lesioned with kainate as described above, allowed to survive for 8 weeks, the animals decapitated and the brains removed, sectioned and prepared for autoradiography. Sections were incubated in 1–6 nM [3H]naloxone, 10 nM delta receptor peptide and 150 mM Tris HCl buffer (pH 7.4) for 1 h at 4 °C. Alternate sections to those exposed to [3H]naloxone were incubated in 1–6 nM [3H]naloxone. 50 mM Tris-HCl (pH 7.4) and 100 mM NaCl. D, E and F are sections serially adjacent to A, B and C, respectively. Each of these photographs was printed individually to optimize the appearance of receptors at each level. Thus, quantitative densitometric comparisons cannot be extrapolated directly from the visual images. GP, Globus pallidus; MT, Medial terminal nucleus of the accessory optic tract; SNr, Substantia nigra pars reticulata.

Fig. 1. Opiate receptor binding one week after a striatal kainate lesion. A–C: [3H]-D-Ala-D-Leu-enkephalin binding to sections through the striatal lesion, lateral globus pallidus and substantia nigra, respectively. Binding was performed in the presence of 5 nM [3H]DADL, 50 mM Tris-HCl (pH 7.4), 30 mM NaCl, 3 mM manganese acetate and 2 μM GTP. D–F: [3H]naloxone binding to brain sections was performed in the presence of 5 nM [3H]naloxone, 50 mM Tris-HCl (pH 7.4) and 100 mM NaCl. D, E and F are sections serially adjacent to A, B and C, respectively. Each of these photographs was printed individually to optimize the appearance of receptors at each level. Thus, quantitative densitometric comparisons cannot be extrapolated directly from the visual images. GP, Globus pallidus; MT, Medial terminal nucleus of the accessory optic tract; SNr, Substantia nigra pars reticulata.
[\textsuperscript{3}H]DADL, 500 nM morphiceptin and 150 mM Tris HCl buffer (pH 7.4) for 1 h at 4 °C. After incubation, slides were washed 6 times in cold 50 mM Tris HCl (pH 7.4) for 20 s each wash. The slides were then dried in a stream of cool air and exposed to Ultratofilm \textsuperscript{3}H (LKB) for 6 weeks. Receptor numbers and affinities were then determined as above.

RESULTS

Autoradiograms of [\textsuperscript{3}H]DADL and [\textsuperscript{3}H]naloxone binding determined by both methods are shown in Figs. 1 and 3. The distribution of binding in cortex and striatum was quite distinctive depending upon the ligand used. This was true independent of the incubation procedure. Nevertheless, the different incubation conditions brought out differences in receptor distribution. [\textsuperscript{3}H]DADL binding was highest in layers II, III and VI of cortex using either technique. In striatum, [\textsuperscript{3}H]DADL binding was relatively uniform but, using the initial incubation conditions, dense 'patches' of binding were readily observed similar to that seen with [\textsuperscript{3}H]naloxone binding. 'Patches' were virtually absent when [\textsuperscript{3}H]DADL binding was performed in the presence of morphiceptin. Cortical [\textsuperscript{3}H]naloxone binding was highest in intermediate layers of cortex. In striatum, dense patches of opiate receptors with lesser concentrations in the background were evident. For both ligands, binding was low in globus pallidus and substantia nigra pars reticulata. A consistent feature in the midbrain with both ligands was a dense strip of binding in the medial nucleus of the accessory optic tract along the medial aspect of nigra. In this study, neither the opiate receptors in patches, nor in the medial nucleus were systematically analyzed because there were not enough serial sections for dose-response curves to be reliable in these areas.

Inspection of the autoradiograms from the first set of animals one week after lesioning revealed a loss of [\textsuperscript{3}H]DADL binding in the striatum. GP and SN, ipsilateral to the lesion (Fig. 1A–C). [\textsuperscript{3}H]Naloxone binding appeared to be decreased in the lesion but not at distant sites (Fig. 1D–F). These observations were confirmed by quantitative densitometry (see Table I). Area measurements of the lesion size in the striatum at multiple levels indicated that, on average, 40% of the head of the caudate was destroyed by the lesion.

Receptor binding in each animal was analyzed by Eadie-Hofstee plots of binding at 4–6 concentrations of each ligand in sections through each structure. In the initial experiment, there were significant reductions in the number of [\textsuperscript{3}H]DADL binding sites in the lesion (67% decrease, \( P < 0.001 \)) and the ipsilateral GP (30% decrease, \( P < 0.01 \)) and SN (41% de-

### TABLE 1

<table>
<thead>
<tr>
<th>Region</th>
<th>([\textsuperscript{3}H]DADL) binding</th>
<th>([\textsuperscript{3}H]naloxone) binding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(B_{max}) (fmol/mg protein)</td>
<td>(K_d) (nM)</td>
</tr>
<tr>
<td>Striatum (n = 9)</td>
<td></td>
<td>Lesioned/ control (× 100)</td>
</tr>
<tr>
<td>Lesioned</td>
<td>211 ± 43**</td>
<td>3.4 ± 0.7</td>
</tr>
<tr>
<td>Control</td>
<td>701 ± 109</td>
<td>3.7 ± 0.4</td>
</tr>
<tr>
<td>Globus Pallidus (n = 9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lesioned</td>
<td>108 ± 11*</td>
<td>2.3 ± 1.0</td>
</tr>
<tr>
<td>Control</td>
<td>157 ± 10</td>
<td>2.0 ± 0.7</td>
</tr>
<tr>
<td>Substantia Nigra (n = 6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lesioned</td>
<td>213 ± 54**</td>
<td>4.2 ± 1.2</td>
</tr>
<tr>
<td>Control</td>
<td>363 ± 99</td>
<td>4.3 ± 0.6</td>
</tr>
</tbody>
</table>

* \( P < 0.01 \) by two-tailed paired \( t \)-test.
** \( P < 0.001 \) by two-tailed paired \( t \)-test.
crease, \( P < 0.01 \) (Fig. 2, Table I). The only significant reduction in \([\text{H}]\text{naloxone} \) binding was a 36% decrease \( (P < 0.01) \) in the lesion. This decrease was significantly less than the decrease in \([\text{H}]\text{DADL} \) binding in the same areas. There were no significant changes in the affinity of binding for either ligand in any of the areas measured.

Using incubation procedures which included either delta receptor peptide or morphiceptin in assays of tissue sections from animals surviving 8 weeks post-lesion, changes in binding similar to those seen acutely (1 week) after striatal lesions were seen in striatum, globus pallidus and nigra (Fig. 3, Table II). Overall \([\text{H}]\text{naloxone} \) and \([\text{H}]\text{DADL} \) binding using this second incubation procedure was less than with the first assay (see Tables I and II) because of the different ionic and nucleotide conditions and because of the cross inhibition of mu and delta sites. Again, the lesion size was about 40% of the head of the caudate. \([\text{H}]\text{DADL} \) binding was decreased 82% \( (P < 0.001) \) at the site of the lesion in striatum, 27% \( (P < 0.01) \) in globus pallidus and 26% \( (P < 0.02) \) in substantia nigra pars reticulata (Fig. 3A–C). \([\text{H}]\text{Naloxone} \) binding was decreased by 20% \( (P < 0.02) \) in striatum, 19% \( (P < 0.05) \) in globus pallidus and non-significantly by 27% in substantia nigra pars reticulata (Fig. 3D–F). In striatum, \([\text{H}]\text{naloxone} \) binding in the 'patches' was decreased dramatically at 8 weeks (but not quantified). This change in the patches was not observed at one week post lesion with either incubation method.

**DISCUSSION**

Striatal kainate lesions caused decreases in opiate binding locally in the striatum and distantly in the globus pallidus and substantia nigra of rats. The magnitude of the receptor changes in the striatal projec-
TABLE II
Opiate receptors eight weeks after unilateral striatal lesions

Assays were as described in the text using the second set of incubation conditions. Values are the average ± S.E.M. The number of animals used for [3H]DADL binding in striatum, GP and SN equaled 6, 6 and 5, respectively. The number of animals used for [3H]naloxone binding in striatum, GP and SN equaled 9, 9 and 8, respectively.

<table>
<thead>
<tr>
<th>Region</th>
<th>[3H]DADL binding</th>
<th>[3H]naloxone binding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$B_{\text{max}}$ (fmol/mg protein)</td>
<td>$K_d$ (nM)</td>
</tr>
<tr>
<td>Striatum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lesioned</td>
<td>35 ± 6$^a$</td>
<td>1.2 ± 0.3</td>
</tr>
<tr>
<td>Control</td>
<td>195 ± 24</td>
<td>2.2 ± 0.4</td>
</tr>
<tr>
<td>Globus Pallidus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lesioned</td>
<td>29 ± 2$^b$</td>
<td>1.4 ± 0.2</td>
</tr>
<tr>
<td>Control</td>
<td>40 ± 2</td>
<td>2.1 ± 0.6</td>
</tr>
<tr>
<td>Substantia Nigra</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lesioned</td>
<td>56 ± 10$^c$</td>
<td>2.8 ± 0.8</td>
</tr>
<tr>
<td>Control</td>
<td>76 ± 12</td>
<td>3.1 ± 0.7</td>
</tr>
</tbody>
</table>

$^a$ $P < 0.001$ by two-tailed paired $t$-test.
$^b$ $P < 0.01$ by two-tailed paired $t$-test.
$^c$ $P < 0.02$ by two-tailed paired $t$-test.
$^d$ $P < 0.05$ by two-tailed paired $t$-test.

tion areas averaged about 30%, consistent with the size of the striatal lesion (which was about 40% of the body of the caudate). These changes were similar to those found for known presynaptic markers of striatal terminals such as levels of GABA, glutamic acid decarboxylase, substance-P and enkephalin itself. These results differ from those that have been found for markers of postsynaptic receptors after striatal lesions. In these studies, there were local decreases in GABA, benzodiazepine, muscarinic cholinergic and dopamine receptors while there were distant increases in GABA and benzodiazepine but not acetylcholine receptors. The latter results were consistent with the development of postsynaptic receptor supersensitivity.

In this study, the findings suggested that opiate binding sites in globus pallidus and substantia nigra existed on striatofugal presynaptic axon terminals. The results were consistent with neurophysiological evidence that enkephalins acted presynaptically on axon terminals to inhibit the release of other neurotransmitters and with anatomical studies showing the presynaptic localization of opiate receptors in striatum and other regions. It might be argued that the local loss of opiate binding seen after striatal lesions was consistent with a postsynaptic location of these binding sites in the striatum. It should be remembered, however, that striatal neurons have a vast number of local recurrent axon collaterals and local release of enkephalin in the striatum has been demonstrated after striatal stimulation. Thus, the most parsimonious explanation for the results found in this study is that a substantial portion of the opiate binding sites in the striatum, pallidum and nigra are on presynaptic terminals of striatal neurons. If this proves true, measurement of opiate binding might serve as a marker for striatal cell loss in animal studies and in human studies using positron emission tomography.

The difference in the binding of [3H]DADL and [3H]naloxone in the lesioned animals was intriguing. Neither [3H]DADL binding nor [3H]naloxone binding was absolutely selective for delta and mu receptors and with each ligand there was a certain amount of labeling of other receptor subtypes. Two different binding assays were used to enhance selective labeling to delta and mu receptors. In each case, the changes in opiate binding after striatal lesions were more significant under conditions which favored binding to delta opiate receptors. An exception to
Fig. 3. Opiate receptor binding 8 weeks after a striatal kainate lesion. A–C: [³H]-d-Ala-d-Leu-enkephalin binding to sections through the striatal lesion, globus pallidus and substantia nigra, respectively. Binding was performed in the presence of 4 nM [³H]DADL, 150 mM Tris HCl (pH 7.4) and 500 nM morphiceptin. D–F: [³H]naloxone binding to sections serially adjacent to those in A–C. Binding was performed in the presence of 5 nM [³H]naloxone, 150 mM Tris HCl (pH 7.4) and 10 nM delta receptor peptide. Each of these photographs was printed individually to optimize the appearance of receptors at each level. Thus, quantitative densitometric comparisons can not be extrapolated directly from the visual images. Abbreviations as in Fig. 1.

This observation was the long term changes seen in [³H]naloxone binding to the ‘patches’. In this study, it was not ascertained whether the changes in binding to the ‘patches’ involved postsynaptic receptor changes or long term degeneration of striatal afferent fibers. Likewise, the possibility of receptor loss due to transsynaptic dendritic degeneration was not evaluated. Transsynaptic degeneration of postsynaptic
dendrites has been observed after decortications and nigrostriatal lesions. Similar transsynaptic degeneration could account for some of the binding changes seen in GP and SNr. Also, it should be noted that not all striatal opiate receptors are thought to be on the axon terminals of striatal neurons. Other investigators have shown that some striatal opiate binding sites are on serotonin and dopamine striatal afferent terminals. Kappa receptor binding also was not assessed in this study but would be of interest since a subset of striatal neurons demonstrate dynorphin-like immunoreactivity and levels of dynorphin are high in substantia nigra pars reticulata.

The role of opiate peptides in striatal function and striatal output is unclear. A large percentage of striatal neurons show opiate-like immunoreactivity. A similarly large proportion of striatal neurons (approximately 70%) demonstrate GAD-like immunoreactivity and levels of GABA are high in substantia nigra pars reticulata.

REFERENCES

18. Graybiel, A. M., Ragsdale, C. W., Yoneoka, E. S. and Elde, R. P., An immunohistochemical study of enkephalins and other neuropeptides in the striatum of the cat with evi-
dence that opiate peptides are arranged to form mosaic patterns in register with the striosomal compartments visible by acetylcholinesterase staining. *Neuroscience*, 6 (1981) 377–397.


